110567-21-0 Usage
Description
(1S, 2R)-2-(Benzyloxymethyl)-1-hydroxy-3-cyclopentene is an organic compound characterized by its unique stereochemistry and functional groups. It is a chiral molecule with a hydroxyl group and a benzyloxy group attached to a cyclopentane ring. (1S, 2R)-2-(Benzyloxymethyl)-1-hydroxy-3-cyclopentene is significant in the field of pharmaceuticals due to its role as a key intermediate in the synthesis of certain drugs.
Uses
Used in Pharmaceutical Industry:
(1S, 2R)-2-(Benzyloxymethyl)-1-hydroxy-3-cyclopentene is used as an intermediate in the synthesis of Entecavir (E558900) for the treatment of hepatitis B infection. Entecavir is an oral antiviral drug that helps in managing and reducing the viral load in patients with chronic hepatitis B, thus preventing the progression of the disease to more severe liver conditions.
The compound's specific stereochemistry and functional groups make it a valuable building block in the synthesis of Entecavir, which is why it is widely used in the pharmaceutical industry for this purpose. Its role in the production of an essential antiviral medication highlights the importance of (1S, 2R)-2-(Benzyloxymethyl)-1-hydroxy-3-cyclopentene in healthcare and the fight against viral hepatitis.
Check Digit Verification of cas no
The CAS Registry Mumber 110567-21-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,5,6 and 7 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 110567-21:
(8*1)+(7*1)+(6*0)+(5*5)+(4*6)+(3*7)+(2*2)+(1*1)=90
90 % 10 = 0
So 110567-21-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H16O2/c14-13-8-4-7-12(13)10-15-9-11-5-2-1-3-6-11/h1-7,12-14H,8-10H2/t12-,13+/m1/s1
110567-21-0Relevant articles and documents
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
-
, (2020/07/31)
The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
-
, (2019/05/30)
The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
The synthesis of possible transition state analogue inhibitors of thymidine phosphorylase
Evans, Gary B.,Gainsford, Graeme J.,Schramm, Vern L.,Tyler, Peter C.
, p. 406 - 409 (2015/04/27)
The synthetically challenging SN2 transition state mimic for thymidine phosphorylase, along with its phosphonate analogue, were synthesised via a modified Corey-Link reaction in good overall yields and ensuring the correct stereochemical outcome.
